Cargando…
Blood pressure targets in patients with chronic kidney disease: MDRD and AASK now confirming SPRINT
Recent American and European hypertension guidelines are not in agreement regarding blood pressure (BP) targets for persons with chronic kidney disease (CKD). Previous analyses from the African American Study on Kidney Disease (AASK) and Modification of Diet in Renal Disease (MDRD) trials suggested...
Autores principales: | Sarafidis, Pantelis, Loutradis, Charalampos, Ortiz, Alberto, Ruilope, Luis M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367111/ https://www.ncbi.nlm.nih.gov/pubmed/32699614 http://dx.doi.org/10.1093/ckj/sfaa015 |
Ejemplares similares
-
Blood pressure targets in CKD 2021: the never-ending guidelines debacle
por: Carriazo, Sol, et al.
Publicado: (2022) -
EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors
por: Fernández-Fernandez, Beatriz, et al.
Publicado: (2023) -
MEDICATION ADHERENCE AND VISIT-TO-VISIT VARIABILITY OF SYSTOLIC BLOOD PRESSURE IN AFRICAN AMERICANS WITH CHRONIC KIDNEY DISEASE IN THE AASK TRIAL
por: Hong, Karen, et al.
Publicado: (2015) -
Simplifying volume assessment with lung ultrasound in paediatric haemodialysis patients
por: Loutradis, Charalampos, et al.
Publicado: (2020) -
SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia
por: Fernandez-Fernandez, Beatriz, et al.
Publicado: (2020)